operational excellence
Process and Performance
„Time, Quality, Cost.“ The old paradigm that you only focus on two and the third would fall into place is no longer valid. The industry requires delivery on time, in full, at quality, and at cost.
Operational excellence is more than just performance boards and a meeting cascade. It requires that people fully understand the ‚why‘ behind everything they do. I look forward to sharing my experience to support you in your improvement journey.
authentic leadership
People and culture
„Culture eats strategy for breakfast.“ So true.
Any transformation or performance improvement program requires that the respective people are fully engaged. More and more, having the right people in the right place is the single most important success factor in our industry.
There is no magic recipe to achieve that, but I am convinced that authentic leadership and being close to the people are key ingredients. Let’s work together on this.
sharing experience
Coaching and Mentoring
As leaders in the industry, we often come from a strong science (technology, engineering) background and were used to mastering what we do through our knowledge. As our careers expand, the weight of science decreases, and relationships, communication, and strategy become more important. Nobody admits that this might become far more difficult (and rewarding) than we ever thought.
During two decades of experience as a leader, with fears, self-doubt, frustrations, but also joy, satisfaction, and learning from great colleagues, I was privileged to have had access to great coaches, mentors, and sparring partners. I am more than happy to share this experience and help you along your way.
implementing visons
Investment and
Site Master Planning
Technology, regulations, and market demands in the biopharmaceutical industry evolve rapidly and continuously. Single-use technologies, process intensification, and robotics.
With my experience in building new plants for drug substances and drug products, as well as developing overall site master plans, I am happy to be your partner in defining and implementing your vision of the future of your assets, tailored to your real needs.“
”Working with Claus proved to be remarkably beneficial in our early-stage assessment of a DACH BioTech investment opportunity. As a sector-generalist investor, we needed to get a grip of a particular BioTech thesis over a short period of time. Claus helped us understand the merits of the situation and unpack a number of highly complex specialist issues in a straightforward no-nonsense way suitable for efficient investment decision making.”
Partner, Private Investment Firm, London
fast and pragmatic evaluation
Evaluation of Assets and
Due Diligences
The industry is going through a wave of mergers and acquisitions, and assets are being offered on the market as ‚fantastic opportunities.‘ Our vast operational experience across various modalities, spanning from R&D to commercial manufacturing, allows for an expert view, along with an idea of potential perspectives.
Besides the actual asset, in other words, the real estate, building, and machines, the less ‚tangible‘ aspects of people, processes, and systems are often neglected. We offer a holistic view and a fast and pragmatic evaluation of what can be achieved and what it will take to get there.
”Claus was extremely helpful in early-stage diligence, helping us focus on the diligence needle-movers and formulate the key questions which we needed to solve. His industry knowledge was also very valuable and allowed him to flag important information which we may have initially overlooked.”
Analyst, Private Equity Group, Madrid
About us
About us
- Owner and President: Dr. Claus Tollnick
- Founded BIOperate Consulting GmbH in 2022
- Leverage More than 25 years of experience in the industry at Sanofi,
Ferring Pharmaceuticals, Recipharm
Claus Tollnick on LINKEDIN - Depending on complexity of projects, working with partners
from my network
Important Trends
Catalent Acquisition by Novo
Holdings – What Does It Mean
for the Industry?
BIOperate! took a closer look at the impact on available capacity for GLP-1 and the potential impact on other CDMO customers, such as smaller biotech companies. Reach out to us for further insights.
Small-Scale Fill and Finish and
Leveraging Robotics
Post-COVID, the industry pursues new approaches to sterile manufacturing: We conducted research on the latest technological advancements. If you need a sparring partner to support your investment decision, let us know.
Biologics, Biosimilars, Injectables: Soon an Easily Accessible Commodity?
The toolboxes for cell lines, manufacturing processes, and even building modular factories have evolved tremendously in the past decade. If you need help making your vision a reality, we are here to help you.
